loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Teprotumumab

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Teprotumumab

    DEVELOPMENTS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Amgen 1Q Results
    Amgen 1Q Results

    21 May 2024

    // CONTRACT PHARMA

    https://www.contractpharma.com/contents/view_breaking-news/2024-05-21/amgen-1q-results/?widget=listSection

    CONTRACT PHARMA
    21 May 2024
    Share Share
    AMGEN to Submit Teprotumumab MAA to EMA
    AMGEN to Submit Teprotumumab MAA to EMA

    26 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/amgen-to-submit-teprotumumab-marketing-authorization-application-to-the-european-medicines-agency-302128358.html

    PR NEWSWIRE
    26 Apr 2024
    Share Share
    Amgen reports 3rd straight sequential sales increase for Tepezza
    Amgen reports 3rd straight sequential sales increase for Tepezza

    07 Feb 2024

    // Kevin Dunleavy FIERCE PHARMA

    https://www.fiercepharma.com/pharma/amgen-expects-revenue-bump-its-acquisition-horizon-between-324b-and-338b

    Kevin Dunleavy FIERCE PHARMA
    07 Feb 2024
    Share Share
    Analysis Highlights Adhering to Uninterrupted Full Course with TEPEZZA
    Analysis Highlights Adhering to Uninterrupted Full Course with TEPEZZA

    29 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230929700356/en

    BUSINESSWIRE
    29 Sep 2023
    Share Share
    Horizon adds 'severe hearing impairment' warning to blockbuster's label
    Horizon adds 'severe hearing impairment' warning to blockbuster's label

    20 Jul 2023

    // Zachary Brennan ENDPTS

    https://endpts.com/horizon-adds-severe-hearing-impairment-warning-to-blockbusters-label/

    Zachary Brennan ENDPTS
    20 Jul 2023
    Share Share
    Horizon's Biologic Tepezza(teprotumumab) Receives Approval in the U.S.
    Horizon's Biologic Tepezza(teprotumumab) Receives Approval in the U.S.

    17 Jul 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761143

    FDA
    17 Jul 2023
    Share Share